Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185616 | 0.90 | FAAH (0.47) | RXFP1EPHX2 | |
| SCHEMBL13117509 | 0.89 | ENPP2 (0.47) | RXFP1ENPP2EPHX2PTGDR2CHRM4 | |
| SCHEMBL10185571 | 0.88 | RXFP1 (0.45) | RXFP1PTGDR2SCN9ADGAT1 | |
| SCHEMBL10185066 | 0.86 | EPHX2 (0.43) | RXFP1EPHX2PTGDR2DGAT1 | |
| SCHEMBL10186490 | 0.86 | ENPP2 (0.42) | RXFP1ENPP2EPHX2PTGDR2CHRM4 | |
| SCHEMBL10186492 | 0.85 | RXFP1 (0.44) | RXFP1SCN9A | |
| SCHEMBL10185386 | 0.85 | RXFP1 (0.43) | RXFP1CD274 | |
| SCHEMBL664096 | 0.85 | RXFP1 (0.44) | RXFP1ENPP2PPARGDGAT1 | |
| SCHEMBL10186305 | 0.85 | RXFP1 (0.44) | RXFP1ENPP2PPARGDGAT1 | |
| SCHEMBL664097 | 0.85 | RXFP1 (0.44) | RXFP1ENPP2PPARGDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | RXFP1 3304/4885ENPP2 812/4885EPHX2 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.